MoneyWorks4Me

Kopran - Quaterly Results

10 Feb 2023 Evaluate
The revenue zoomed 24.54% to Rs. 679.64 millions for the quarter ended December 2022 as compared to Rs. 545.73 millions during the corresponding quarter last year.Profit after tax for the quarter ended December 2022 reported a huge growth of 74.09% to Rs. 40.44  millions from Rs. 23.23 millions.The company reported a good operating profit of 72.63 millions compared to 50.34 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 679.64 545.73 24.54 1927.67 1400.18 37.67 2045.20 2228.33 -8.22
Other Income 11.60 15.80 -26.58 160.71 59.03 172.25 80.27 104.14 -22.92
PBIDT 72.63 50.34 44.28 345.62 144.79 138.70 234.40 406.14 -42.29
Interest 7.22 9.75 -25.95 18.30 21.56 -15.12 29.53 38.07 -22.43
PBDT 65.41 40.59 61.15 327.32 123.23 165.62 204.87 368.07 -44.34
Depreciation 11.19 10.98 1.91 33.23 32.63 1.84 43.23 41.03 5.36
PBT 54.22 29.61 83.11 294.09 90.60 224.60 161.64 327.04 -50.57
TAX 13.78 6.38 115.99 36.74 20.90 75.79 44.20 92.33 -52.13
Deferred Tax 0.45 1.31 -65.65 -2.31 5.07 -145.56 6.73 34.76 -80.64
PAT 40.44 23.23 74.09 257.35 69.70 269.23 117.44 234.71 -49.96
Equity 482.11 432.52 11.47 482.11 432.52 11.47 482.12 432.52 11.47
PBIDTM(%) 10.69 9.22 15.85 17.93 10.34 73.39 11.46 18.23 -37.12
Peers
Company Name CMP
Sun Pharma. Inds. 1835.50
Dr. Reddys Labs. 1171.10
Cipla 1371.45
Lupin 2144.70
Zydus Lifesciences 1153.00
View more..